KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Assets (2017 - 2025)

Historic Current Assets for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $151.7 million.

  • Aquestive Therapeutics' Current Assets rose 5706.02% to $151.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.7 million, marking a year-over-year increase of 5706.02%. This contributed to the annual value of $88.2 million for FY2024, which is 11534.93% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Current Assets stood at $151.7 million for Q3 2025, which was up 5706.02% from $81.7 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Current Assets registered a high of $151.7 million during Q3 2025, and its lowest value of $38.1 million during Q3 2022.
  • For the 5-year period, Aquestive Therapeutics' Current Assets averaged around $65.7 million, with its median value being $47.3 million (2021).
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 2414.46% in 2022, then surged by 16141.3% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Current Assets (Quarter) stood at $47.3 million in 2021, then decreased by 15.6% to $39.9 million in 2022, then increased by 2.7% to $41.0 million in 2023, then soared by 115.35% to $88.2 million in 2024, then surged by 71.93% to $151.7 million in 2025.
  • Its last three reported values are $151.7 million in Q3 2025, $81.7 million for Q2 2025, and $89.2 million during Q1 2025.